About Inspira Technologies Oxy B.H.N. Ltd. - Ordinary Shares (IINN)
Inspira Technologies Oxy B.H.N. Ltd is a medical technology company focused on developing innovative solutions for respiratory support and oxygen therapy. The company aims to improve patient outcomes through advanced oxygenation technology designed to enhance the efficiency and effectiveness of oxygen delivery in various clinical settings. By leveraging cutting-edge research and development, Inspira Technologies seeks to address the challenges related to respiratory care, ultimately contributing to better healthcare solutions for patients in need. Read More
RA'ANANA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), today announced the commencement of an AME technology implementation with a customer that is one of the world's 10 largest U.S.-based companies. This engagement marks a significant step in the practical execution of the Company's strategic expansion into advanced technology markets following its acquisition of the AME (Additive Manufactured Electronics) business, including Inspira's entry into the cryogenic connectivity space for quantum computing, where the AME platform is being leveraged to address one of the most critical scaling bottlenecks facing the quantum industry today.The rollout has already commenced and is focused on advancing Inspira's AME technology at a U.S. research and development facility, integrated into one of the world's most advanced corporate technology infrastructures. The customer operates at the forefront of artificial intelligence, computing infrastructure, and platform technologies globally.The Company believes this implementation process provides high-level validation of its AME platform and reflects ongoing commercial engagement with a customer operating at the highest tier of the global corporate technology landscape. Importantly, this engagement reinforces recurring revenue-generating activity associated with that customer relationship. Furthermore, the process demonstrates broader demand from elite technology organizations for solutions addressing next-generation hardware connectivity and integration challenges."We view this type of engagement as confirmation of the practical relevance of our AME platform," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "We are not speaking about theoretical potential. We are engaged in an active implementation process with a paying customer ranked among the largest companies in the world, a company with the resources, expertise, and infrastructure to validate our AME technology at the highest level. We view this engagement as an important signal of where this platform can go."Inspira believes that the customer’s participation in this type of implementation process supports additional strategic opportunities and further strengthens the positioning of its AME platform across advanced technology markets.
RA'ANANA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”) today announced its entry into the quantum computing sector, targeting a critical connectivity bottleneck by directing its recently acquired additive manufactured electronics (“AME”) platform toward a new 3D architecture for systems operating in dilution cryostats.
The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500 device’s functionality, design, and clinical applications.
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Market News Alerts Reports: Inspira Technologies (NASDAQ: IINN)* is reported beginning deployment of its FDA-cleared INSPIRA ART100 system at a leading New York cardiothoracic program ranked among the top 15% nationally, marking a significant commercialization milestone in a sector experiencing unprecedented M&A activity. The medtech industry saw multiple billion-dollar acquisitions in 2024, including Johnson & Johnson's $13.1 billion acquisition of Shockwave Medical, Edwards' $4.2 billion sale of its Critical Care business to BD, and Boston Scientific's $3.7 billion Axonics purchase.
PESG Research releases an update following Inspira Technologies' (NASDAQ: IINN)* recent strategic developments and clinical achievements: Inspira has emerged as a potential disruptive force in respiratory care with its integrated technology approach. The company's recent clinical studies demonstrating 96% accuracy for its AI-powered HYLA blood sensor represent a significant technological validation as it targets multiple high-value healthcare segments.
PESG Research releases an update following groundbreaking clinical evaluation results: Inspira Technologies* (NASDAQ: IINN) has reported exceptional clinical study outcomes for its HYLA blood sensor, with 96% accuracy achieved in a key parameter compared to traditional blood analyzers. This milestone achievement validates the company's AI-powered continuous blood monitoring technology and accelerates its path toward commercial deployment in multiple healthcare settings.
Inspira Technologies OXY B.H.N. announced positive initial results from collaboration with Ennocure MedTech to develop bio-electronic treatment for preventing bloodstream infections. Promising ex-vivo testing showed 95% reduction in bacterial presence within 4 hours and potential for extended wear time.
Future Markets Research Releases an update following recent developments: Inspira Technologies* (NASDAQ: IINN) has announced a significant advancement in its AI-driven medical platform with the integration of a next-generation oxygenation indicator into its HYLA blood sensor technology. This enhancement enables rapid detection of critical oxygen-related conditions without requiring intermittent blood draws, representing a potential breakthrough in continuous patient monitoring.
Inspira Technologies integrates an AI-powered oxygenation indicator into its HYLA sensor, aiming to enhance real-time monitoring and critical care capabilities.
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per share. Reneo Pharmaceuticals shares climbed 13.6% to $1.59 on Wednesday.
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list its financial arm in October 2025.
Shares of Ascent Industries Co. (NASDAQ: ACNT) rose sharply in pre-market trading as the company reported the sale of the business of Specialty Pipe & Tube for around $55 million in an all-cash deal. Ascent Industries shares surged 7.4% to $8.69 in pre-market trading.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The S&P 500 also rose, gaining, 0.45% to 4,776.17.
